Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2014 / Cilt: 22 - Sayı: 1

Sıçanlarda alt ekstremite iskemisi ve reperfüzyonu ile tetiklenen akciğer hasarının azaltılmasında pentoksifilin, iloprost ve silostazolün proenflamatuvar sitokin aracılı koruyucu etkileri

The proinflammatory cytokine-mediated protective effects of pentoxifylline, iloprost, and cilostazol on a mitigating lung injury induced by lower limb ischemia and reperfusion in rats

Pages
138–144
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In this acute lung injury model induced by I/R of the lower limbs, pretreatment with pentoxifylline, iloprost and cilostazol significantly attenuated pro- inflammatory activities and parenchymal lung damage

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This study aims to elucidate whether pentoxifylline, iloprost and cilostazol mitigates acute lung injury induced by lower limb ischemia-reperfusion (I/R) and their protective effects cover cytokines.
📊
Key Findings & Data:Methods: Forty rats were randomized into five groups: control (group 1), ischemia-reperfusion (group 2), pentoxifylline (group 3), iloprost (group 4), iloprost and cilostazol (group 5).
💡
Conclusion & Impact:Conclusion: In this acute lung injury model induced by I/R of the lower limbs, pretreatment with pentoxifylline, iloprost and cilostazol significantly attenuated pro- inflammatory activities and parenchymal lung damage
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: This study aims to elucidate whether pentoxifylline, iloprost and cilostazol mitigates acute lung injury induced by lower limb ischemia-reperfusion (I/R) and their protective effects cover cytokines. Methods: Forty rats were randomized into five groups: control (group 1), ischemia-reperfusion (group 2), pentoxifylline (group 3), iloprost (group 4), iloprost and cilostazol (group 5). All drugs were administered before ischemia. Samples were obtained for tumor necrosis factor- alpha (TNF-a), interleukin 6 (IL-6), and total sialic acid (TSA) assays. Findings of lung injury were examined. Results: Interleukin-6 and TNF levels were increased at 90 minutes and sustained elevated even after 240 minutes. In groups 3 and 4, IL-6 and TNF levels were significantly lower at 90, 180 and 240 minutes compared to group 2. At 180 minutes, TSA levels in groups 2, 3, 4 and 5 were significantly different from baseline and 90 minute levels. At this time point, TSA levels of group 2 and 3 were significantly higher compared to group 4 and 5. Conclusion: In this acute lung injury model induced by I/R of the lower limbs, pretreatment with pentoxifylline, iloprost and cilostazol significantly attenuated pro- inflammatory activities and parenchymal lung damage

Özet

Amaç: Bu çalışmada, pentoksifilin, iloprost ve silostazolün alt ekstremite iskemisi-reperfüzyonu ile tetiklenen akut akciğer hasarını azaltıp azaltmadığı ve bu koruyucu etkilere sitokinlerin dahil olup olmadığı araştırıldı.Ça­lış­ma­ pla­nı:­ Kırk sıçan rastgele beş gruba ayrıldı: kontrol (grup 1), iskemi-reperfüzyon (grup 2), pentoksifilin (grup 3), iloprost (grup 4), iloprost ve silostazol (grup 5). Tüm ilaçlar iskemi öncesi uygulandı. Tümör nekroz faktör-alfa (TNF-a), interlökin-6 (IL-6) ve total sialik asit (TSA) incelemeleri için numuneler alındı. Akciğer hasarı bulguları incelendi.Bul gu lar: İnterlökin-6 ve TNF düzeylerinde 90. dakikada artış olduğu ve hatta 240. dakikadan sonra da yüksek seyrettiği saptandı. Grup 3 ve 4'de, IL-6 ve TNF düzeyleri, grup 2 ile karşılaştırıldığında 90, 180. ve 240. dakikalarda anlamlı olarak düşüktü. Total sialik asit düzeyleri 180. dakikada grup 2, 3, 4 ve 5'te bazal ve 90. dakikadaki değerlerden anlamlı olarak farklı idi. Bu zaman noktasında TSA düzeyleri grup 2 ve 3'te grup 4 ve 5 ile karşılaştırıldığında anlamlı derecede yüksekti.So nuç: Alt ekstremite İ/R ile tetiklenmiş bu akut akciğer hasarı modelinde, pentoksifilin, iloprost ve silostazol ile ön tedavinin uygulanması, proinflamatuvar aktiviteyi ve parankimal akciğer hasarını anlamlı düzeyde azaltmıştır

🔖

Cite This Article

YILDIZ, E., UĞUZ, E., BERKAN, Ö., ÖZERDEM, G., HIDIROĞLU, M. (2022). Sıçanlarda alt ekstremite iskemisi ve reperfüzyonu ile tetiklenen akciğer hasarının azaltılmasında pentoksifilin, iloprost ve silostazolün proenflamatuvar sitokin aracılı koruyucu etkileri. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 22 - Sayı: 1, 138–144. https://ajindex.com/articles/424315

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Welbourn R, Goldman G, O’Riordain M, Lindsay TF, Paterson IS, Kobzik L, et al. Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. J Appl Physiol (1985) 1991;70:2645-9
  2. Tassiopoulos AK, Carlin RE, Gao Y, Pedoto A, Finck CM, Landas SK, et al. Role of nitric oxide and tumor necrosis factor on lung injury caused by ischemia/reperfusion of the lower extremities. J Vasc Surg 1997;26:647-56
  3. Seekamp A, Warren JS, Remick DG, Till GO, Ward PA. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 1993;143:453-63
  4. Berkan O, Göl MK, Içağasioğlu S, Cetnkaya O, Yildiz E, Doğan K, et al. Sialic acid is a marker of lung injury following lower extremities ischemia/reperfusion. Eur J Vasc Endovasc Surg 2004;27:553-8
  5. Anner H, Kaufman RP Jr, Valeri CR, Shepro D, Hechtman HB. Reperfusion of ischemic lower limbs increases pulmonary microvascular permeability. J Trauma 1988;28:607-10
  6. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97
  7. Lessa A, Suguihara C, Xianyu S, Hehre D, Devia C, Bancalari E. The effect of pentoxifylline on the pulmonary response to high tidal volume ventilation in rats. Pulm Pharmacol Ther 2008;21:54-60
  8. Iyú D, Glenn JR, White AE, Johnson AJ, Fox SC, Heptinstall S. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function. Platelets 2010;21:329-42
  9. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924
  10. Koksel O, Ozdulger A, Aytacoglu B, Tamer L, Polat A, Sucu N, et al. The influence of iloprost on acute lung injury induced by hind limb ischemia-reperfusion in rats. Pulm Pharmacol Ther 2005;18:235-41
  11. Sahin MA, Onan B, Guler A, Oztas E, Uysal B, Arslan S, et al. Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury. Heart Surg Forum 2011;14:E171-7
  12. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9
  13. Mazzone A, Faggioli P, Cusa C, Stefanin C, Rondena M, Morelli B. Effects of iloprost on adhesion molecules and F1 + 2 in peripheral